Figure 6.

Augmented humoral responses to ATP6S1 in vaccinated metastatic melanoma and NSCLC patients and a CML patient treated with CD4⁺ DLI. Patient sera were used in an ELISA at a 1:500 dilution and developed with an anti-human IgG secondary antibody. The small arrows denote vaccinations, and the bold arrows indicate resections of distant metastases. (A) Melanoma patient K030. (B) NSCLC patient L1. (C) NSCLC patient L33. (D) CML patient C1. DLI was administered on day 0, and clinical, cytogenetic, and molecular responses began at day 80.